huahaipharm(SH:600521) Xin Lang Cai Jing·2025-09-22 07:23Core Viewpoint - Huahai Pharmaceutical's stock has experienced a decline of 5.04% over the past three days, closing at 22.43 CNY per share with a market capitalization of 33.583 billion CNY [1] Company Overview - Zhejiang Huahai Pharmaceutical Co., Ltd. was established on February 28, 2001, and listed on March 4, 2003. The company specializes in the research, production, and sales of various dosage forms of generic drugs, biological drugs, innovative drugs, and specialty raw materials [1] - The revenue composition of the company is as follows: finished drug sales account for 61.86%, raw materials and intermediates sales for 36.75%, other sales for 0.78%, and technical services for 0.62% [1] Fund Holdings - According to data, one fund under Jiashi Fund holds a significant position in Huahai Pharmaceutical. Jiashi Xinhe One-Year Holding Period Mixed A (008664) held 50,300 shares in the second quarter, representing 0.39% of the fund's net value, making it the sixth-largest holding [2] - The fund has incurred a floating loss of approximately 26,700 CNY today, with a total floating loss of 59,900 CNY during the three-day decline [2] Fund Manager Information - The fund manager of Jiashi Xinhe One-Year Holding Period Mixed A (008664) is Yang Yechao, who has been in the position for 9 years and 303 days. The total asset size of the fund is 1.878 billion CNY [3] - During Yang Yechao's tenure, the best fund return was 40.38%, while the worst return was -4.07% [3]